Review of Epemdymoma in the Shohada-y- Tajrish Hospital

Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:

Ependymoma constitute 5 % to 7 % of all primary CNS neoplasm. But their prevalence relative to other tumor type varies with patient age and presenting location. Ependymoma constitute approximately 1O % of intracranial neoplasm in pediatric population and up to 30 % of those encountered in children under 3 years of age. In spinal column, ependymoma constitute 60% of glial neoplasm, and opposed to intracranial tumors. These neoplasm exhibit a decided preditection for the fourth and five decade of life In these research which has done upon 25 patients with ependymoma in the Shohadaye Tajrish Hospital during the years 1372 to 1376, Thirteen of patients are male and 12 of them are female. The tumor has been more common between the ages of 0-20 years old in intracranial neoplasm and 21-30 years old in intraspinal neoplasm. Headache and lumbar pain have been the most common clinical manifestation. The majority (22) of lesions in conventional histologic grading have been low grade (Grade I,II) and the rest (3) high grade (grade III.IV).

Language:
Persian
Published:
Journal of Research In Medical Sciences, Volume:24 Issue: 3, 2000
Pages:
165 to 170
magiran.com/p2307196  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!